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TreatmentA B S T R A C T
Cogan’s syndrome is a rare disorder characterized by ocular and audiovestibular manifestations
in its typical form and caries a wide variety of atypical manifestations. It is considered as an
autoimmune disease. We present the ﬁrst case in the literature of a 67 year old woman with
the development of low grade non-Hodgkin lymphoma (NHL) in the mastoid bone in a pre-
existing history of atypical Cogan’s syndrome. The anatomical development of NHL was to
a ‘‘target’’ organ of Cogan’s syndrome, which is the inner ear.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
We present a rare case of the development of low grade
non-Hodgkin lymphoma (NHL) in the mastoid bone in apatient with an atypical Cogan’s syndrome without
progression of NHL and with symptomatic deterioration of
Cogan’s syndrome, responding only to TNF-a modulation.Case presentation
A 67 year old female Caucasian patient from Greece presented
in April 2003 with intermittent fevers up to 38 C. Two months
later she complained for additional persistent headaches, bilat-
eral hearing loss, vertigo, tinnitus, and episodes of ataxia.
Audiovestibular manifestations were classiﬁed as sensorineural
524 C. Kalogeropoulos et al.deafness. In September 2003 she was admitted to the hospital
where an extensive workup was negative except of a brain
MRI which showed a presence of a mass lesion over the right
mastoid outgrowth (Fig. 1A and B). She underwent surgical
biopsy and histologic evaluation revealed a low grade B-cell
non-Hodgkin’s lymphoma (NHL) (ICD10:C85) (Fig. 2A and
B). Staging evaluation proved to be of IB. She was managed
with six cycles of chlorambucil till June 2004, with complete
remission of the malignant lesion.
In April 2005 the patient referred to the ophthalmology
department with main complains a severe impairment of visual
acuity and ocular pain in both eyes. It is worth mentioning that
medical history revealed that the patient had experienced epi-
sodes of mild visual disturbances during the last semester of
2003 and throughout 2004 overlooked by her. Quite long inter-
vals between visits for follow up and management occurred
because of patient poor compliance. In ophthalmologic exam-
ination Snellen visual acuity was found to be 0.2 on the right
and 0.3 on the left eye; bilateral panuveitis (anterior chamber
reaction and vitritis) along with papilledema and increased
intraocular pressure in both eyes was diagnosed. Laboratory
workup including intraocular ﬂuid studies with PCR, cultures
and ﬂow cytometry was not diagnostic; elevated serum IgG
titers against CMV were only found. Investigation for tubercu-
losis, syphilis and sarcoidosis was also negative. The patient
was initially considered as a case of CMV associated uveitis
treated with intravitreal injection of ganciclovir, cycloplegics,
topical steroids and periocular steroid injections. Patient’s ocu-
lar manifestations were markedly improved (Snellen visual
acuity: 0.7 in each eye and remission of uveitis signs).
However, audiovestibular and institutional manifestations
were gradually deteriorated and in June 2006 she was pre-
sented with deafness, arthritis, fever, anemia and skin rash
whereas, neither oral aphthous along with genital ulceration
were observed nor had been ever reported. Ocular manifesta-
tions were still under control. The clinical presentation mainlyFig. 1 (A) Axial T2-weighted scan (TR/4000 ms, TE/250 ms) demons
large part of the right mastoid. Mastoiditis at the periphery of the lesi
components appear normal with the expected high signal. (B) Axial c
level with (A) demonstrates an enhancing tissue (white arrowhead)
periphery of the lesion appears with intermediate signal intensity (whitthe audiovestibular and ocular manifestations was indicative
of Cogan’s syndrome in its atypical form. Full serum autoim-
mune proﬁle (including antinuclear antibodies, anti-dsDNA
antibodies and c-antineutrophil cytoplasmic antibodies)
and infectious proﬁle were negative, except for the presence
of an IgG monoclonal protein band as well as for elevated
erythrocyte sedimentation rate and C-reactive protein
levels.
Due mainly to the continuous clinical deterioration of
fever, fatigue, headache, skin rash and arthralgias led in
November 2007 to the re-administration of chlorambucil and
methylprednisolone for another six cycles. During the admin-
istration of methylprednisolone skin rash, fever and fatigue
got better, only for a short period of time. The patient was
practically deaf, with mild visual disturbances, fever, fatigue,
malaise, symmetric polyarthritis and cutaneous manifesta-
tions. A cutaneous lesion biopsy revealed granuloma annulare.
Systematic follow up was negative for NHL progression. The
patient was managed from December 2008 till January 2009
with two cycles of cyclophosphamide, vincristine and methyl-
prednisolone and from January till February 2009 with two
cycles of rituximab without response.
In February 2009 patient’s ocular disturbances recurred
with ocular pain and markedly decreased visual acuity (Snellen
visual acuity: 0.025 on the right and 0.1 on the left eye). Cytol-
ogy of aqueous humor demonstrated inﬂammatory cells with
the predominance of lymphocytes, ﬁndings suggestive of
chronic active inﬂammation (uveitis). In the absence of pro-
gression of NHL disease and given the fact that our patient
was getting worse she was administered inﬂiximab, an anti
TNF-a agent, as a third line treatment for Cogan’s syndrome
and systemic steroids. Ocular pain and visual acuity were
improved (Snellen visual acuity: 0.2 on the right and 0.3 on
the left eye) and inﬂammation regressed, while bilateral papil-
ledema was still present (Fig. 3). Audiovestibular, general
symptoms and skin manifestations were moderately improved.trating a low signal intensity tissue (white arrowhead) occupying a
on appears with high signal intensity (white arrow). The inner ear
ontrast enhanced T1-weighted scan (TR/500 ms, TE/20 ms) same
occupying a large part of the right mastoid. Mastoiditis at the
e arrow). No contrast enhancement was observed at the inner ear.
Fig. 2 Mastoid mucosal biopsy inﬁltrated by atypical lymphoid
neoplastic cells, mainly B differentiated (L26+) with T reactive
lymphocytes (UCLH1+) between the neoplastic cells. The mitotic
count, using the immunohistochemical marker Ki67, was low
(<5%). (A) Hematoxylin-Eosin stain in magniﬁcation 40·. (B)
L26 stain in magniﬁcation 40·.
Fig. 3 Funduscopic examination with evidence of bilateral
papilledema.
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In 1945 Cogan’s described a clinical entity which consisted of
ocular manifestations of non-syphilic interstitial keratitis and
of audiovestibular manifestations of Meniere-like symptoms.
Meniere-like symptoms in Cogan’s syndrome are bilateral,
more pronounced, long lasting and may lead to more severe
vestibular abnormalities, such as ataxia or oscillopsia. That
entity was called after his name and is known till today as
Cogan’s syndrome. Later in 1980, Haynes et al. broadened
the diagnostic criteria and enclosed other ocular and audioves-
tibular manifestations and manifestations from other organs,
all of which are known as atypical forms of Cogan’s syndrome.
Haynes et al. proposed the criteria by which atypical Cogan’s
syndrome would be recognized and these include: (1) inﬂam-
matory ocular manifestations (episcleritis, scleritis, choroiditis,
papilloedema, retinal hemorrhage, retinal artery occlusion,
exophthalmos or tendonitis) in the presence or absence of
interstitial keratitis, isolated conjunctivitis, subconjunctivalhemorrhage or iritis only in combination with Meniere like
symptoms within 2 years of symptoms onset, (2) audiovestibu-
lar symptoms other than Meniere like manifestations com-
bined with typical ocular manifestations within 2 years of
symptoms onset and (3) the presence of typical ocular and
audiovestibular manifestations in a period of time more than
2 years between them [1–3].
There are no speciﬁc laboratory tests for diagnosing
Cogan’s syndrome, except the exclusion of syphilis by serolog-
ical test. In clinical practice it is sometimes difﬁcult to classify
between typical or atypical Cogan’s syndrome, because its
physical history may vary considerably. Audiovestibular dis-
turbances can proceed or can appear simultaneously or it
may follow ocular manifestations. However, since vestibuloau-
ditory manifestations may precede other symptoms and signs,
diagnosis of Cogan’s syndrome should not be overlooked by
ophthalmologists in all patients with delayed recurrent ocular
inﬂammation associated with vestibuloauditory symptoms.
According to a work of the Study Group for Cogan’s Syn-
drome [1] ocular and audiovestibular manifestations occurred
closely or even simultaneously in most cases with typical
Cogan’s syndrome whereas in atypical Cogan’s syndrome the
mean interval between the mentioned manifestations was
27.1 months. Table 1 summarizes various signs and symptoms
other than ocular and audiovestibular manifestations that can
be present, both in typical and in atypical forms of syndrome
[1,2]. Although the classiﬁcation of a patient in typical or atyp-
ical Cogan’s syndrome can be misleading, the existing data are
not efﬁcient enough to prove that this classiﬁcation can have
an effect on treatment plan or patient outcome.
Cogan’s syndrome is recently being regarded as an autoim-
mune disorder due to the presence of autoantibodies against the
inner ear and endothelium. In mice preclinical models it has
Table 1 Signs and symptoms other than ocular and audiovestibular manifestations in typical and atypical forms of Cogan’s
syndrome.
System Manifestations
Constitutional Fever, malaise, myalgias, headache, fatigue, weight loss
Gastrointestinal Abdominal discomfort, mouth ulcers, peptic and colonic ulceration with bleeding
Musculoskeletal Myalgias, arthritis, arthralgias
Cutaneous Skin rash, nodules, vitiligo, non-speciﬁc urticarial rash, nodules or ulceration of limbs, pyoderma gangrenosum
Cardiac ﬁndings Aortic insuﬃciency, aortitis, cardiomegaly, congestive heart failure
Renal Membranoproliferative glomerulonephritis, renal failure
Vasculitis Phlebitis, vasculitis, polyarteritis nodosa, diﬀuse vasculitis
Nervous Central: Meningitis, encephalitis, myelopathy, cerebellar syndrome
Peripheral: paraesthesias of extremities, trigeminal neuralgia, mononeuritis multiplex
Genitourinary Mild abnormalities in urinalysis, La Peyronie syndrome with orchitis
Others Lymphadenopathy, splenomegaly, hypertension, eosinophilia
526 C. Kalogeropoulos et al.been proved that the intravenous administration of autoanti-
bodies found in patients with Cogan’s syndrome reproduced
the classic pathologic manifestations of the syndrome, such as
tissue damage of inner ear, endothelial cells and cornea [4].
The association of atypical Cogan’s syndrome with systemic
diseases such as rheumatoid arthritis, juvenile arthritis, Sjo-
gren’s syndrome, sarcoidosis, Crohn disease, ulcerative colitis
and Wegener’s granulomatosis has also been described and in
suspected atypical Cogan’s syndrome investigation aims to rule
out systemic lupus erythematosus and Adamantiades-Behcet’s
disease. In addition, it has been proposed that patients with
atypical Cogan’s syndrome may be at higher risk of developing
neurological symptoms, lymphadenopathy and splenomegaly
[1]. Approximately, 70% of these patients have systemic mani-
festations, of which vasculitis is considered the pathogenic
mechanism and therefore carries a less favorable prognosis
than typical Cogan’s syndrome [1,5]. In a retrospective review
two patients with Cogan’s syndrome had a history of B-cell
lymphoma but in none of them malignancy was developed on
the preexisting autoimmune lesion [2]. Recently an atypical
Cogan’s syndrome presenting as bilateral endogenous endoph-
thalmitis in a woman with ovarian cancer was reported [6].
The control of symptoms is achieved mainly by the admin-
istration of glucocorticosteroids. The most responsive symp-
toms are the ocular ones (as in our patient), in contrast to
the audiovestibular manifestations which are more resistant
to therapy. The sooner the steroid administration from the
onset of symptoms the better the outcome is. Ocular symptoms
are managed quite sufﬁciently and permanent visual loss has
rarely been reported, in contrast to audiovestibular manifesta-
tions which after consecutive deterioration usually lead to per-
manent deafness [1].
After failure of glucocorticosteroids, ‘‘second line’’ therapy
is immunosuppressive drugs such as azathioprine, cyclophos-
phamide, methotrexate and cyclosporine. The best responses
have been observed with methotrexate [1,7]. Inﬂiximab might
be an alternative therapy for Cogan’s syndrome, especially in
cases where corticosteroids and immunosuppressive therapy
have failed. Treatment might be more effective when started
at an early stage of the inner-ear disease, when the lesions
are still reversible [8]. Apart from the administration of the
aforementioned agents, surgical interventional techniques such
as cochlear implants or hearing aids devices have reported
promising results with improved hearing capacity [9–11].Our patient suffered from atypical form of Cogan’s syn-
drome and developed B-cell low grade NHL in the mastoid
bone. Her NHL responded well to therapy, but Cogan’s
syndrome symptoms gradually worsened with the additional
cutaneous and institutional manifestations. We speculate that
the development of NHL was not accidental, but occurred
on the basis of the preexisting immune abnormality and
the anatomical distribution of NHL occurred to the organ
‘‘target’’ for Cogan’s syndrome that is the inner ear. In
line with this, literature indicates the high risk of NHL
development mainly in major autoimmune diseases and the
anatomical relationship between them, such as the NHL devel-
opment in target organs such as glandular parotid in Sjogren’s
syndrome [12].Conclusions
Cogan’s syndrome is a rare clinical entity; infectious and
immunological causes have been implicated as triggering
factors. Several immune system functional disorders are
associated with an increased risk of malignant transformation.
As lymphoma is a cancer of the immune system that originates
from B and T cells, it seems reasonable that immune dysfunc-
tion may lead to occurrence of immune malignancies [13]. On
the other hand Cogan’s syndrome developing in a HIV patient
and regressing after administration of antiretroviral therapy
was also reported recently [14]. Our hypothesis that the
development of NHL in our patient with atypical Cogan’s syn-
drome occurred due to an altered immunity background with
the anatomical relevance agrees with the existing literature.Conﬂict of interest
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